Imperative Care Completes Initial Closing of Series E Financing for up to $150 Million; Shacey Petrovic Appointed to Vice Chair, Board of Directors
Imperative Care, a medical technology company focused on stroke and ischemic diseases, has announced the initial closing of an oversubscribed Series E financing led by Ally Bridge Group. The financing, which may raise up to $150 million in total, includes participation from existing and new investors. The funds will support the company's hypergrowth strategy and investment in novel technologies and clinical evidence.
Additionally, Shacey Petrovic has been appointed to the newly created position of Vice Chair of the Board of Directors. Petrovic, who joined the board in 2023, will focus on scaling strategies to bring life-changing technologies to more patients. She previously served as President and CEO of Insulet and currently sits on the boards of Exact Sciences (EXAS), Ambu A/S, and Axena Health.
Imperative Care, un'azienda di tecnologia medica specializzata in ictus e malattie ischemiche, ha annunciato la chiusura iniziale di un finanziamento di Serie E sovrascritto guidato da Ally Bridge Group. Il finanziamento, che potrebbe raccogliere fino a $150 milioni in totale, include la partecipazione di investitori esistenti e nuovi. I fondi supporteranno la strategia di ipercrescita dell'azienda e l'investimento in tecnologie innovative e prove cliniche.
In aggiunta, Shacey Petrovic è stata nominata per la nuova posizione di Vicepresidente del Consiglio di Amministrazione. Petrovic, che è entrata nel consiglio nel 2023, si concentrerà su strategie di scalabilità per portare tecnologie che cambiano la vita a un numero maggiore di pazienti. In precedenza ha ricoperto il ruolo di Presidente e CEO di Insulet e attualmente fa parte dei consigli di Exact Sciences (EXAS), Ambu A/S e Axena Health.
Imperative Care, una empresa de tecnología médica centrada en el accidente cerebrovascular y enfermedades isquémicas, ha anunciado el cierre inicial de una financiación de Serie E sobre suscrita liderada por Ally Bridge Group. La financiación, que puede recaudar hasta $150 millones en total, incluye la participación de inversores existentes y nuevos. Los fondos apoyarán la estrategia de hipercrecimiento de la empresa y la inversión en tecnologías novedosas y evidencia clínica.
Además, Shacey Petrovic ha sido nombrada para el nuevo puesto de Vicepresidente de la Junta Directiva. Petrovic, quien se unió a la junta en 2023, se enfocará en estrategias de escalabilidad para llevar tecnologías que cambian la vida a más pacientes. Anteriormente, fue Presidenta y CEO de Insulet y actualmente forma parte de las juntas de Exact Sciences (EXAS), Ambu A/S y Axena Health.
임페라티브 케어(Imperative Care)는 뇌졸중 및 허혈 질환에 집중하는 의료 기술 회사로, 앨리 브리지 그룹(Ally Bridge Group)이 주도하는 시리즈 E 자금조달의 초기 마감을 발표했습니다. 이 자금 조달은 최대 $150백만 달러를 모금할 수 있으며, 기존 및 신규 투자자들의 참여가 포함되어 있습니다. 이 자금은 회사의 가파른 성장 전략과 혁신적인 기술 및 임상 증거에 대한 투자 지원에 사용될 예정입니다.
추가로, 셰이시 페트로빅이 새로 창설된 이사회 부회장으로 임명되었습니다. 2023년에 이사회에 합류한 페트로빅은 환자들에게 생명을 변화시키는 기술을 제공하기 위한 확장 전략에 집중할 것입니다. 그녀는 이전에 인슐렛(Insulet)의 사장 겸 CEO로 재직했으며, 현재 엑자트 사이언스(Exact Sciences, EXAS), 암부(Ambu A/S), 악세나 헬스(Axena Health)의 이사회에도 참여하고 있습니다.
Imperative Care, une entreprise de technologie médicale axée sur les AVC et les maladies ischémiques, a annoncé la clôture initiale d'un financement de série E sursouscrit dirigé par Ally Bridge Group. Le financement, qui pourrait atteindre jusqu'à 150 millions de dollars au total, comprend la participation d'investisseurs existants et nouveaux. Les fonds soutiendront la stratégie de hypercroissance de l'entreprise et l'investissement dans des technologies novatrices et des preuves cliniques.
De plus, Shacey Petrovic a été nommée à la nouvelle position de Vice-présidente du Conseil d'Administration. Petrovic, qui a rejoint le conseil en 2023, se concentrera sur les stratégies d'échelle pour apporter des technologies qui changent la vie à davantage de patients. Elle a précédemment occupé le poste de Présidente et CEO d'Insulet et siège actuellement dans les conseils de Exact Sciences (EXAS), Ambu A/S et Axena Health.
Imperative Care, ein Medizintechnikunternehmen, das sich auf Schlaganfall und ischämische Erkrankungen konzentriert, hat den ersten Abschluss einer überzeichneten Serie E-Finanzierung unter der Leitung der Ally Bridge Group angekündigt. Die Finanzierung könnte insgesamt bis zu 150 Millionen USD einbringen und umfasst die Beteiligung bestehender und neuer Investoren. Die Mittel werden die Hyperwachstumsstrategie des Unternehmens sowie Investitionen in neuartige Technologien und klinische Beweise unterstützen.
Zudem wurde Shacey Petrovic zur neu geschaffenen Position des Vorsitzenden des Vorstands ernannt. Petrovic, die 2023 dem Vorstand beigetreten ist, wird sich auf Skalierungsstrategien konzentrieren, um lebensverändernde Technologien einem größeren Patientenkreis zugänglich zu machen. Zuvor war sie Präsidentin und CEO von Insulet und sitzt derzeit in den Vorständen von Exact Sciences (EXAS), Ambu A/S und Axena Health.
- Oversubscribed Series E financing with potential to raise up to $150 million
- Strong investor support from existing and new investors
- Company has treated over 45,000 patients with life-saving technologies
- Appointment of experienced executive Shacey Petrovic as Vice Chair of the Board
- None.
Financing Fuels the Company’s Hypergrowth to Make Elevated Care Accessible to More Patients
Petrovic’s Appointment Positions Imperative Care for Long Term Success and Scale
The financing was led by Ally Bridge Group with participation from other existing investors, including D1 Capital Partners, AMED Ventures, Bain Capital Life Sciences, Rock Springs Capital Management LP, Innovatus Capital Partners, LLC and Pura Vida Investments. The financing also included participation from new investors, including Catalio Capital Management, LP, HealthCor Family Office, Montreux Growth Partners, and INTAI Technology Corp.
“We are grateful for the continued support of our existing investors and welcome our new investors who share our vision for leadership in stroke and vascular thrombectomy,” said Fred Khosravi, Chairman and CEO of Imperative Care. “This latest financing fuels our hypergrowth strategy as we work to make better care accessible to more patients. We will continue to invest in novel technologies and clinical evidence to measure the impact of these technologies on patient outcomes.”
“As investors in Imperative Care since the company’s Series C financing in December 2019, we have been impressed with the dramatic progress the company has made on many fronts, including treating more than 45,000 patients with life-saving technologies,” said Ally Bridge founder and CEO Frank Yu, who has also served as a Director on the Imperative Care Board since 2019. “We are excited to support the next stage of Imperative Care’s success, as the company strengthens its position for treating ischemic stroke and prepares to make a major contribution to the treatment of peripheral vascular disease.”
After the initial closing and subject to the discretion of the Company, there may be additional closings of this Series E financing, raising up to
Appointment of Shacey Petrovic to Vice Chair, Board of Directors
The company also announced the appointment of Shacey Petrovic to the newly created position of Vice Chair of its Board of Directors. Petrovic joined the Imperative Care Board in 2023. In the role of Vice Chair, Petrovic will focus on strategies to scale the company with the goal of bringing life-changing technologies to more patients suffering from stroke and other devastating vascular diseases.
Petrovic also serves on the Boards of Exact Sciences (NASDAQ: EXAS), Ambu A/S (OTC US: AMBBY) and Axena Health. Previously, Petrovic served on the board and was President and CEO of Insulet Corporation (NASDAQ: PODD), a diabetes technology company. Under her leadership, Insulet grew to serve hundreds of thousands of people with diabetes across the globe.
“It has been a privilege to benefit from Shacey’s business acumen and strategic mastery as we position Imperative Care for long term success and scale,” Khosravi said. “On behalf of our Board of Directors, I would like to congratulate Shacey on her appointment to Vice Chair as we continue to build the thrombectomy company of the future with the patient at the center.”
“I am excited to step into this new leadership role as Imperative Care accelerates its work to deliver impactful innovations to patients at the most tenuous moments of their lives,” said Petrovic. “My experience serving on the Imperative Care Board has been quite inspirational as the company engineers solutions to some of the greatest challenges in medicine through medtech and digital health innovations.”
About Imperative Care, Inc.
Imperative Care is a commercial-stage medical technology company researching and developing connected innovations to elevate care for people affected by devastating vascular diseases such as stroke and pulmonary embolism. The company is focused on addressing specific gaps in treatment and care to make an impact across the entire patient journey. Imperative Care is based in
Legal Disclaimer / Forward-Looking Statements
This press release is not an offer to sell securities or a solicitation of an offer to buy any securities, and may not be relied upon in connection with the purchase or sale of any company security. This release may contain forward-looking statements regarding plans for future financing, projected business performance, future innovations and improvement of patient outcomes. Such statements are forward-looking statements and there can be no assurance that the results stated or implied by these forward-looking statements will actually be realized or achieved by the company. Forward-looking statements may be based on management assumptions that could prove to be wrong. The company’s predictions may not be realized for a variety of reasons as the company’s business is subject to substantial risks and potential events beyond its control that could cause material differences between predicted and actual results.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240725822876/en/
Investor:
Matt Garrett, CFO
Imperative Care, Inc.
408-476-1672
mgarrett@imperativecare.com
Media:
Jana Chow
Imperative Care, Inc.
925-324-9846
jchow@imperativecare.com
Source: Imperative Care, Inc.
FAQ
How much did Imperative Care raise in its Series E financing?
Who led Imperative Care's Series E financing round?
What is Shacey Petrovic's new role at Imperative Care?
What other company boards does Shacey Petrovic serve on, including EXAS?
